Expertise in
12
conditions

Dr. Helen J. Ross

Rush University Medical Group
Chicago, IL
Expertise in
12
conditions
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
41 Years of Experience
Expertise in
12
conditions
OverviewInsuranceLocationsClinical Research

Overview

Helen Ross is a Hematologist Oncology specialist and an Oncologist in Chicago, Illinois. Dr. Ross has been practicing medicine for over 41 years is highly rated in 12 conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Stent Placement. Dr. Ross is currently accepting new patients.

Her clinical research consists of co-authoring 30 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1984
Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Rush University Medical Center
Languages Spoken
English
Spanish
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  UnitedHealthcare
  •  Oscar

Locations

RUSH UNIVERSITY MEDICAL GROUP
1725 W Harrison St, Suite 1010, Chicago, IL 60612
312-942-5904

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drugs: Atezolizumab, Cisplatin, Pemetrexed Disodium
Study Phase: Phase 1
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)
A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drugs: Ceritinib (LDK378), Nivolumab
Study Phase: Phase 1
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2024
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 05, 2024
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
Enrollment Status: Completed
Publish Date: March 25, 2024
Intervention Type: Other, Drug
Study Drugs: Auranofin, Sirolimus
Study Phase: Phase 1/Phase 2
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2024
Intervention Type: Drug, Procedure, Radiation
Study Drug: Durvalumab
Study Phase: Phase 2
Randomized Phase II Study of Standard Chemotherapy With Docetaxel With or Without Bintrafusp Alfa in Patients With Advanced NSCLC After Progressing on a Combination of Anti-PD-1/PD-L1 Agents and Chemotherapy
Randomized Phase II Study of Standard Chemotherapy With Docetaxel With or Without Bintrafusp Alfa in Patients With Advanced NSCLC After Progressing on a Combination of Anti-PD-1/PD-L1 Agents and Chemotherapy
Enrollment Status: Terminated
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Docetaxel
Study Phase: Phase 2
Phase I/II Study of the Human Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine (AR), Combined With the PD-L1 Inhibitor Atezolizumab in Non-Small Cell Lung Cancer
Phase I/II Study of the Human Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine (AR), Combined With the PD-L1 Inhibitor Atezolizumab in Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 06, 2023
Intervention Type: Biological, Other
Study Phase: Phase 1
Phase 1b/Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
Phase 1b/Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: May 02, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 13 Less Clinical Trials

30 Total Publications

Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
Journal: JAMA oncology
Published: July 25, 2024
Similar Doctors
Expertise in
29
conditions
Dr. Sonali M. Smith
Hematology Oncology | Hematology | Oncology
Expertise in
29
conditions
Dr. Sonali M. Smith
Hematology Oncology | Hematology | Oncology

University Of Chicago

355 E Grand Ave, 
Chicago, IL 
 (3.0 mi)
888-824-0200
Languages Spoken:
English, Greek, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Smith is highly rated in 29 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is currently accepting new patients.

Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology Oncology | Oncology | Hematology
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology Oncology | Oncology | Hematology

Northwestern Medical Faculty Foundation

676 N Saint Clair St, Suite 850, 
Chicago, IL 
 (2.8 mi)
312-695-6180
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leo Gordon is a Hematologist Oncology specialist and an Oncologist in Chicago, Illinois. Dr. Gordon is highly rated in 33 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gordon is currently accepting new patients.

Reem M. Karmali
Expertise in
26
conditions
Dr. Reem M. Karmali
Hematology Oncology | Hematology | Oncology
Expertise in
26
conditions
Dr. Reem M. Karmali
Hematology Oncology | Hematology | Oncology

Northwestern Medical Faculty Foundation

250 E Superior St, 
Chicago, IL 
 (3.0 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Reem Karmali is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Karmali is highly rated in 26 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Karmali is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile